HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Crucial Information Coming On GSK's Investor Day Includes Consumer Health Spin-Out Details

Executive Summary

Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.

You may also be interested in...



Blow For CureVac As COVID-19 Vaccine Hits 47% Efficacy

CureVac is not throwing in the towel just yet, but the odds are stacked against a successful end result.

GSK Sees Other Side Of Consumer Health Stockpiling Coin, Looks Ahead To Business Split

GSK reports pandemic-related stockpiling in 2020 combined with a weak cold and flu season in Q1 drove its consumer health sales down 9%, with the sharpest downturn in respiratory products sales. The firm expects in the second half of the year to see “more normal consumer trends.”

GSK's ICOS Agonist Disappointment Another Setback For Anticancer Ambitions

GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS151466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel